Article Text

Download PDFPDF
Palliative radiation treatment used for multiple purposes in a single irradiation field
  1. Kosei Miura1,2,
  2. Hiromasa Kurosaki1 and
  3. Nobuko Utsumi1
  1. 1Department of Radiation Therapy, JCHO Tokyo Shinjuku Medical Center, Shinjuku-ku, Japan
  2. 2Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan
  1. Correspondence to Dr Kosei Miura; kousei951378246{at}gmail.com

Abstract

In this case report, radiation therapy was performed for bilateral hydronephrosis developed during multiple bone metastases of breast cancer and ileus due to peritoneal dissemination. The patient’s preirradiation creatinine level was 8.2 mg/dL, which decreased by the fourth day after starting irradiation therapy. Creatinine level ultimately decreased to 0.6 mg/dL. Pain due to lumbar spine metastasis alleviated and ileus was resolved, allowing the patient to live at home for approximately 5 weeks. The effect of radiotherapy for bilateral hydronephrosis and gastrointestinal obstruction was rapid and good. Palliative radiation treatment can be used for multiple purposes, and in the present patient, we were able to prolong the vital prognosis.

  • end of life decisions (palliative care)
  • renal medicine
  • radiotherapy
  • breast cancer
  • pain (palliative care)

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors KM, HK and NU were responsible for the conception and design of the work, as well as data collection, analysis and interpretation. KM and HK drafted the the article. KM, HK and NU participated in the critical revision of the article and final approval of the version to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.